Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Other Financing Activities

Financing cash flows not reported separately.

Grifols, S.A.NASDAQ: GRFS

Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026

Other financing activities turns negative

Q2 FY2026 other financing activities was -€47.68M, compared with €537.35M a year earlier. Trailing-twelve-month other financing activities was -€251.57M. Over 3 fiscal years it compounded at +29.7% a year.

Context

  • Other financing activities amounted to 2.0% of revenue in FY2025, down 15.3 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other financing activities holds near -€47.68M or moves back toward the trailing-twelve-month quarterly average of -€62.89M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€47.68M+260.8% QoQ
Last fiscal yearDec 2025
-€142.26M-88.6% YoY
LTMJun 2026
-€251.57M-105.6% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.9%——
1 year-88.6%——
3-year CAGR+29.7%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

EUR · from the cash flow

Latest · FY2025
(142.26M) EUR
Year-over-year change
+88.6%

Other Financing Activities vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -105.6% is the 8th highest of 9, against a peer median of +105.5%.
  • Other financing activities amounts to 3.4% of revenue for GRFS, versus a peer median of 0.9%.
GRFS Competitors
Other Financing Activities for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BDXBecton, Dickinson and CompanyLTM Sep 2026$3.4B USD+4008.0%—16.8%
GRFSGrifols, S.A.LTM Jun 2026€251.57M EUR-105.6%+29.7%3.4%
ABTAbbott LaboratoriesLTM Jun 2026$100M USD+185.7%—0.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$25.1M USD+25.4%—1.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$14.22M USD+1077.9%-60.9%6.8%
ADMAADMA Biologics, Inc.LTM Jun 2026$12.08M USD+302.1%+16.6%2.4%
TECHBio-Techne CorporationLTM Sep 2026$10.15M USD-129.7%+99.2%0.8%
QDELQuidelOrtho CorporationLTM Mar 2026$5.1M USD-86.0%-51.1%0.2%
HAEHaemonetics CorporationLTM Jun 2026$286K USD-99.6%-31.3%0.0%
Peer median (excluding GRFS) —+105.5%-31.3%0.9%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income188.73M361.26M207.02M444M386.13M
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(181.36M)(609.22M)(362.84M)22.38M(24.01M)
Accounts Receivables(16.81M)(80.17M)(68.82M)(41.88M)(30.74M)
Inventory(157.47M)(600.25M)(411.44M)25.82M(93.17M)
Accounts Payables080.21M0090.29M
Other Working Capital(7.08M)(9.01M)117.41M38.44M9.61M
Other Non-Cash Items229.84M(173.89M)(71.91M)(2.1M)211.32M
Operating Cash Flow596.98M(10.87M)218.69M902.17M1.01B
Capital Expenditures(247.37M)(375.56M)(310.32M)(371.37M)(254.54M)
Acquisitions (Net)(519.13M)(1.44B)(29.47M)(285.87M)(99.9M)
Purchases of Investments0(164.66M)(93.31M)(43.85M)(54.75M)
Sales of Investments0015.14M04.8M
Other Investing Activities(87.65M)3.28M(62.64M)1.45B0
Investing Cash Flow(854.15M)(1.98B)(394.72M)886.67M(556.15M)
Debt Repayment2.75B(104.29M)(116.39M)(111.49M)(119M)
Common Stock Issued00000
Common Stock Repurchased(125.7M)(3.46M)00(123.91M)
Dividends Paid(252.44M)(592K)0(962K)(122.95M)
Other Financing Activities(70.56M)(65.16M)287.89M(1.25B)(142.26M)
Financing Cash Flow2.3B(173.49M)171.49M(1.36B)(508.12M)
Effect of Forex Changes55.46M35.55M(15.09M)20.08M19.75M
Net Change in Cash2.1B(2.13B)(19.63M)450.2M(38.85M)
Free Cash Flow349.6M(386.43M)(91.63M)530.8M751.14M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.